Interspecies differences in physiology and pharmacology: Extrapolating preclinical data to human populations

Preclinical Drug Development

Volumn , Issue , 2005, Pages 11-66

  Martinez, Marilyn N ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85128126235     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (170)

1. Li AP. Overview: hepatocytes and cryopreservation - a personal historical perspective. Chemico-Biol Intervent 1999; 121:1-5.
2. Nomeir AA, Markham P, Burka LT, Griffin RJ, Ghanayem BI. Species differences in the disposition and metabolism of nalidixic acid. J Pharm Exp Therap 1996; 279:222-230.
3. Lewis RW, Billington R, Debryune E, Gamber A, Lang B, Carpanini F. Recognition of adverse and nonadverse effects in toxicity studies. Toxicol Pathol 2002; 30:66-74.
4. Gad SC, Chengelis CP. Acute Toxicology Testing. 2d ed. San Diego: Academic Press, 1998.
5. Burger GT, Renne RA, Sagartz JW, Ayres PH, Coggins CRE, Mosberg AT, Hayes AW. Histological changes in the respiratory tract induced by inhalation of xenobiotics: physiologic adaptation or toxicity? Toxicol Appl Pharmacol 1989; 101:521-542.
6. Alcock SJ. An anti-inflammatory compound: non-toxic to animals, but with an adverse action in man. Proc Eur Soc Stud Drug Toxicol 1971; 12:184-190.
7. Barnes CD, Eltherington LG. Drug Dosage in Laboratory Animals. Berkley and Los Angeles: University of California Press, 1965.
8. Ritschel WA, Siegel EG, Ring PE. Biopharmaceutical factors influencing LD50 Part I: viscosity. Arzneim-Forsch (Drug Res) 1974; 24:907-910.
9. Martinez M, Augsburger L, Johnston T, Jones WW. Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part I: biopharmaceutics and formulation considerations. Adv Drug Deliv Rev 2002; 54:805-824.
10. 2 cell layers and everted gut sacs of rats. Biochem Pharmacol 2000; 59:665-672.
11. Dudeja PK, Anderson KM, Harris JS, Buckingham L, Coon JS. Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch Biochem Biophys 1995; 319:309-315.
12. Yamazaki T, Sato Y, Hanai M, Mochimaru J, Tsujino I, Sawada U, Horie T. Non-ionic detergent Tween 80 modulates VP-16 resistance in classical multidrug resistant K562 cells via enhancement of VP-16 influx. Cancer Lett 2000; 149:153-161.
13. Woodcock DM, Jefferson S, Linsenmeyer ME, Crowther PJ, Chojnowski GM, Williams B, Bertoncello I. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 1990; 50:4199-4203.
14. Chang T, Benet LZ, Hebert MF. The effect of water-soluble vitamin E on cyclosporin pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 1996; 59:297-303.
15. Hottendorf GH. Species differences in toxic lesions. In: Roloff MV, ed. Human Risk Assessment-The Role of Animal Selection and Extrapolation. New York: Taylor Francis, 1987:87-95.
16. Schein PS, Davis RD, Carter S, Newman J, Schein DR, Rall DP. The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man. Clin Pharmacol Ther 1970; 11:3-40.
17. Monroe A, Mordenti J. Expression of exposure in negative carcinogenicity studies: dose/body weight, dose/body surface area, or plasma concentrations? Toxicol Pathol 1995; 23:187-198
18. Reinhard MK, Hottendorf GH, Powell ED. Differences in the sensitivity of Fischer and Sprague-Dawley rats to aminoglycoside toxicity. Toxicol Pathol 1991; 19:66-71.
19. Ader R. N Cohen Psychoneuroimmunology: conditioning and stress. Annu Rev Psychol 1993; 44:53-85.
20. Morris TH. Antibiotic therapeutics in laboratory animals. Lab Anim 1995; 29:16-36.
21. Reinberg A, Smolensky MH. Circadian changes of drug disposition in man. Clin Pharmacokinet 1982; 7:401-420.
22. Straka RJ, Benson SR. Chronopharmacologic considerations when treating the patient with hypertension: a review. J Clin Pharmacol 1996; 36:771-782.
23. Smolensky MH, D'Alonzo GE. Biologic rhythms and medicine. Am J Med 1988; 85:34-46.
24. Labrecque G, Bureau J-P, Reinberg AE. Biological rhythms in the inflammatory response and in the effects of non-steroidal anti-inflammatory drugs. Pharmacol Ther 1995; 66:285-300.
25. Blumenthal RD, Waskewich C, Goldenberg DM, Lew W, Flefleh C, Burton J. Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts. Clin Cancer Res 2001; 7:3178-3185.
26. Hla KK, Latham AN, Henry JA. Influence of time of administration on verapamil pharmacokinetics. Clin Pharmacol Ther 1992; 51:366-370.
27. Bruckner JV, Ramanathan R, Lee KM, Muralidhara S. Mechanisms of circadian rhythmicity of carbon tetrachloride hepatotoxicity. J Pharmacol Exp Ther 2002; 300:273-281.
28. Furukawa T, Manabe S, Watanabe T, Sharyo S, Mori Y. Sex difference in the daily rhythm of hepatic P450 monooxygenase activities in rats is regulated by growth hormone release. Toxicol Appl Pharmacol 1999; 161:219-224.
29. Martinez M, Amidon G, Clarke L, Jones WW, Mitra A, Riviere J. Applying the biopharmaceutics classification system to veterinary pharmaceutical products: Part II. Physiological considerations. Adv Drug Deliv Rev 2002; 54:825-850.
30. Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 2002; 42:620-643.
31. Pardue RL, White C. Chronokinetics of liposomal encapsulated ampicillin in fasting and nonfasting rats. J Pharm Sci 1996; 85:309-312.
32. Newberne PM, Conner MW. The role of diet and nutrition in safety evaluation of drugs and other chemicals. In: Roloff MV, ed. Human Risk Assessment-The Role of Animal Selection and Extrapolation. New York: Taylor and Francis, 1987:65-79.
33. Ammouche A, Dinhl L, Youyou A, Clement M, Bourre JM. Rate of alteration of hepatic mixed function oxidase system in rats fed different dietary fats. Biochem Cell Biol 1993; 71:530-553.
34. Brunner LJ, Bai S. Effect of dietary oil intake on hepatic cytochrome P450 activity in the rat. J Pharm Sci 2000; 89:1022-1027.
35. National Toxicology Program, Comparative Toxicology Studies of Corn Oil, Safflower Oil, and Tricaprylin (CAS Nos. 8001-30-7, 8001-23-8, and 538-23-8) in male F334/N Rats as Vehicles for Gavage, NTP TR 426, NIH Publication No. 94-3157, April 1994.
36. Gad SC, Chengelis CP. In: Animal Models in Toxicology. New York: Marcel Dekker, 1992.
37. Gaines TB. Acute toxicology of pesticides. Toxicol Appl Pharmacol 1969; 14:515-534.
38. Reinoso RF, Farran R, Moragon T, Garcia-Soret A, Martinez L. Pharmaco-kinetics of E-6087, a new anti-inflammatory agent, in rats and dogs. Biopharm Drug Dispos 2001; 22:231-242.
39. Niwa T, Kaneko H, Naritomi Y, Togawa A, Shiraga Y, Iwasaki K, Tozuka Z, Hata T. Species and sex differences of testosterone and nifedipine oxidation in liver microsomes of rat, dog and monkey. Xenobiotica 1995; 25:1041-1049.
40. Shanor SP, van Hees GR, Baart N, Erdos EG, Foldes EF. The influence of age and sex on human plasma and red cell cholinesterase. Am J Med Sci 1961; 242:357-361.
41. Eben A, Pilz W. Abhangigbeit der Acetylcholinesterase-acktivatat in Plasma and Erythrocyten von der alter und geschlecht de Ratte. Arc Toxicol 1967; 23:27-34.
42. Naik SR, Anjaria RJ, Sheth UK. Studies on rat brain acetylcholine and cholinesterase. Pt 1. Effect of body weight, sex, stress and CNS depressant drugs. Ind J Med Res 1970; 58:473-479.
43. Caldwell J. The current status of attempts to predict species differences in drug metabolism. Drug Metab Rev 1981; 12:221-237.
44. Boxenbaum H, DiLea C. First-time-in-human dose selection: allometric thoughts and perspectives. J Clin Pharmacol 1995; 35:957-966.
45. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Braken W, Dorato M, Van Deun D, Smith P, Berger B, Heller A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Tox Pharm 2000; 32:56-67.
46. Stevens CE, Humes ID. Comparative Physiology of the Vertebrate Digestive System. New York: Cambridge University Press, 1995.
47. Cunningham JG. Textbook of Veterinary Physiology. London: W.B. Saunders, 1997.
48. Baggot JD, Brown SA. Basis for selection of the doage form. In: Hardee GE, Baggot JD, eds. 2d ed. Development and Formulation of Veterinary Dosage Forms. 2 New York: Marcel Dekker, 1998:7-143.
49. Titkemeyer CW, Calhoun ML. A comparative study of the structure of the small intestine of domestic animals. Am J Vet Res 1955; 58:152-158.
50. Yamada A, Furuya M, Akimoto T, Maki T, Suwa H, Ogata H. Evaluation of gastrointestinal transit controlled-beagle dog as a suitable animal model for bioavailability testing of sustained-release acetaminophen dosage form. Int J Pharm 1995; 119:1-10.
51. Aoyagi N, Ogata H, Kaniwa N, Koibuchi M, Shibazaki T, Ejima A, Tamaki N, Kamimura H, Katougi Y, Omi Y. Bioavailability of griseofulvin from tablets in beagle dogs and correlation with dissolution rate and bioavailability in humans. J Pharm Sci 1982; 10:1169-1172.
52. Walker RM, Smith GS, Barsoum NJ, Macallum GE. Preclinical toxicology of the anticonvulsant calcium valproate. Toxicology 1990; 63:137-155.
53. Uchida T, Kawata M, Goto S. In vivo evaluation of ethyl cellulose microcapsules containing ampicillin using rabbits, beagle dogs and humans. J Pharma-cobiodyn 1986; 8:631-637.
54. Aoyagi N, Ogata H, Kaniwa N, Uchiyama M, Yasuda Y, Tanioka Y. Gastric emptying of tablets and granules in humans, dogs, pigs and stomach-emptying-controlled rabbits. J Pharm Sci 1992; 81:1170-1174.
55. Kaniwa N, Aoyagi N, Ogata H, Ejima A. Gastric emptying rates of drug preparations. I. Effects of size of dosage forms, food and species on gastric emptying rates. J Pharmacobiodyn 1988; 11:563-570.
56. Swenson MJ. Duke's Physiology of Domestic Animals. 10th ed. New York: Cornell University Press, 1984.
57. Kabanda L, Lefebve RA, Van Bree HJ, Remon JP. In vitro and in vivo evaluation in dogs and pigs of a hydrophilic matrix containing propylthiouracil. Pharm Res 1994; 11:1663-1668.
58. Aoyagi N, Ogata H, Kaniwa N, Ejima A. Bioavailability of indomethacin capsules in humans. (I): Bioavailability and effects of gastric acidity. Int J Clin Pharmacol Ther Toxicol 1985; 9:469-474.
59. Ogata H, Aoyagi N, Kaniwa N, Ejima A. Effect of food on bioavailability of metronidazole from sugar-coated tablets having different dissolution rates in subjects with low gastric acidity. Int J Clin Pharmacol Ther Toxicol 1986; 6:279-282.
60. Tokumura T, Tsushima Y, Tatsuishi K, Kayano M, Machida Y, Nagai T. Enhancement of the oral bioavailability of cinnarizine in oleic acid in beagle dogs. J Pharm Sci 1987; 76:286-288.
61. Akimoto M, Nagahata N, Furuya A, Fukushima K, Higuchi S, Suwa T. Gastric pH profiles of beagle dogs and their use as an alternative to human testing. Eur J Pharm Biopharm 2000; 49:99-102.
62. Kararli TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 1995; 5:351-380.
63. Choe SY, Amidon GL. Modern Biopharmaceutics with Capsugel Library (C.D. version 4.0). TSRL, Inc., 2000.
64. Edwards GA, Christopher JH, Caliph SM, Khoo SM, Charman WN. Animal models for the study of intestinal lymphatic drug transport. Adv Drug Deliv Rev 2001; 50:45-60.
65. Nordskog BA, Pham CT, Nutting DF, Tso P. An examination of the factors affecting intestinal lymphatic transport of dietary lipids. Adv Drug Deliv Rev 2001; 50:21-44.
66. Wilding I. Site-specific drug delivery in the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst 2000; 17:557-620.
67. Thummel KE, Kunze KL, Shen DD. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 1997; 27:99-127.
68. Van Gelder J, Shafiee M, De Clercq E, Penninckx F, Van den Mooter G, Kinget R, Augustijns P. Species-dependent and site-specific intestinal metabolism of ester prodrugs. Int J Pharm 2000; 205:93-100.
69. Lin JH, Chiba M, Baillie TA. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 1999; 51:135-157.
70. Lin JH. Applications and limitations of interspecies scaling and in-vitro extrapolation in pharmacokinetics. Drug Metab Disp 1998; 26:1202-1212.
71. Yeh KE, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, Justice SJ, Osborne B, Sterrett AT, Stone JA, Woolf E, Waldman S. Single-dose pharma-cokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 1998; 42:332-338.
72. Chiou WL, Barve A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 1998; 15:1792-1795.
73. Chiou WL, Jeong HY, Chung SM, Wu TC. Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res 2000; 17:135-140.
74. Ilett KF, Tee LBG, Reeves PT, Minchin RF. Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmac Therap 1990; 46:67-93.
75. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinetic 1994; 26:144-160.
76. Kaminsky LS, Fasco MJ. Small intestinal cytochromes P450. Crit Rev Toxicol 1992; 21:407-422.
77. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998; 87:1322-1330.
78. Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ. Intestinal MDR transport proteins and P450 enzyme as barriers to oral drug delivery. J Cont Rel 1999; 62:23-31.
79. Dresser MJ. The MDR1, C3435T polymorphism: effects on p-glycoprotein expression/function and clinical consequences. AAPS PharmSci Special Volume: Pharmacogenetics-Pharmacogenomics, 2001.
80. Goh LB, Spears KJ, Yao D, Ayrton A, Morgan P, Wolf CR, Friedberg T. Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem Pharmacol 2002; 64:1569-1578.
81. Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 1998; 15:1160-1167.
82. Saitoh H, Aungst BJ. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm Res 1995; 12:1304-1310.
83. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci 1997; 94:2031-2035.
84. Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001; 31:469-497.
85. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Rockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with p-glycoprotein expression and activity in vivo. Proc Natl Acad Sci 2000; 97:3473-3478.
86. Davis LE, Neff CA, Baggot JD, Powers TE. Pharmacokinetics of chloramphenicol in domesticated animals. Am J Vet Res 1972; 33:2259-2266.
87. Aldercreutz H, Pulkkinen MO, Hamalainen EK, Korpela JT. Studies on the role of intestinal bacteria in metabolism of synthetic and natural steroid hormones. J Steroid Biochem 1984; 20:217-229.
88. Hawksworth G, Drasar BS, Hill MJ. Intestinal bacteria and the hydrolysis of glycosidic bonds. J Med Microbiol 1971; 4:451-459.
89. Kenyon EM, Calabrese EJ. Extent and implications of interspecies differences in the intestinal hydrolysis of certain glucuronide conjugates. Xenobiotica 1993; 4:373-381.
90. Bazzol F, Fromm H, Sarve RP, Sembra RF, Ceryak S. Comparative formation of lithocholic acid from chenodeoxycholic acid and ursodeoxycholic acids in the colon. Gastroenterology 1982; 83:753-760.
91. Suzuki H, Hamada M, Kato F. Metabolism of lithocholic and chenodeoxycholic acids in the squirrel monkey. Gastroenterology 1985; 89:631-636.
92. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JH, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, Shipley LA. Contemporary issues in toxicology: drug metabolites in safety testing. Toxicol Appl Pharmacol 2002; 182:188-196.
93. Chiu SHL, Huskey SEW. 1996 ASPET N-glucuronidation of xenobiotics symposium. Species differences in n-glucuronidation. Drug Metab Disp 1998; 26:838-847.
94. Collins JM. Inter-species differences in drug properties. Chem Biol Interact 2001; 134:237-242.
95. Cayen MN. Retrospective evaluation of appropriate animal models based on metabolism studies in man. In: Roloff MV, ed. Human Risk Assessment: The Role of Animal Selection and Extrapolation. Philadelphia, PA: Taylor and Francis Ltd, 1987:99-113.
96. Mahmood I. Allometric issues in drug development. J Pharm Sci 1999; 88:1101-1106.
97. Zhou SF, Tingle MD, Kestell P, Paxton JW. Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo. Xenobiotica 2002; 32:87-107.
98. Caldwell J, Gardner I, Swales N. An introduction to drug disposition: the basic principles of absorption, distribution, metabolism and excretion. Toxicol Pathol 1995; 23:102-114.
99. Vargas M, Franklin MR. Intestinal UDP-glucuronosultransferase activities in rat and rabbit. Xenobiotica 1997; 27:413-421.
100. van't Klooster GA, Horback GJ, Natsuhori M, Blaauboer BJ, Noordhoek J, van Miert AS. Heptaic cytochrome P450 induction in goats. Effects of model inducers on the metabolism of alkoxyresorufins, testosterone, ethylmorphine, and on apoprotein and mRNA levels. Biochem Pharmacol 1993; 45:113-122.
101. Baggot JD. Pharmacokinetic-pharmacodynamic relationship. Ann Rech Vet 1990; 21(suppl 1):29s-40s.
102. Ruelius HW. Extrapolation from animals to man: predictions, pitfalls and perspectives. Xenobiotica 1987; 17:255-265.
103. Guengerich FP. Characterization of roles of human cytochrome P-450 enzymes in carcinogen metabolism. Asia Pacific J Pharmacol 1990; 5:327-345.
104. Smith DA, Abel SM, Hyland R, Jones BC. Human cytochrome P450s: selectivity and measurement in vivo. Xenobiotica 1998; 28:1095-1128.
105. Berthou F, Guillois B, Riche C, Dreano Y, Jacqz-Aigrain E, Beaune PH. Interspecies variation in caffeine metabolism related to cytochrome P450 1A enzymes. Xenobiotica 1992; 22:671-680.
106. Walton K, Dorne JL, Renwick AG. Uncertainty factors for chemical risk assessment: interspecies differences in the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates. Food Chem Toxicol 2001; 39:667-680.
107. Soucek P, Gut I. Review: cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica 1991; 22:83-103.
108. Kitamura S, Nakatani K, Ohashi K, Sugihara K, Hosokawa R, Akagawa Y, Ohta S. Extremely high drug-reductase activity based on aldehyde oxidase in monkey liver. Biol Pharm Bull 2001; 24:856-859.
109. Stevens JC, Shipley LA, Cashman JR, Vandenbranden M, Wrighton SA. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities. Drug Metab Disp 1993; 21:753-760.
110. Pelkonen O, Sotaniemi EA, Ahokas JT. Coumarin 7-hydroxylase activity in human liver microsimes. Properties of the enzyme and interspecies comparison. Br J Clin Pharmacol 1988; 19:59-66.
111. Raunio H, Syngelma T, Pasanen M, Juvonen R, Honkakoski P, Kairaluoma MA, Sotaniemi E, Lange MA, Pelkonen O. Immunochemical and catalytic studies on hepatic coumarin 7-hydroxylase in man, rat and mouse. Biochem Pharmacol 1988; 37:3889-3895.
112. Sharer JE, Shipley LA, Vandenbranden MR, Binkley SN, Wrighton SA. Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey and cynomolgus monkey. Drug Metab Disp 1995; 23:1231-1241.
113. Mulder GJ, Coughtrie MWH, Burchell B. Glucuronidation in conjugation reactions in drug metabolism. In: Mulder GL, ed. Drug Metabolism. London: Taylor and Francis Ltd, 1990:51-105.
114. Huskey SW, Miller RR, Chiu SHL. N-glucuronidation reactions. I. tetrazole N-glucuronidation of selected angiotensin II receptor antagonists in hepatic microsomes from rats, dogs, monkeys and humans. Drug Metab Disp 1993; 21:792-799.
115. CDER: Draft Guidance for Industry: Nonclinical Safety Evaluation of Pediatric Drugs. February, 2003.
116. Renwick AG. Toxicokinetics in infants and children in relation to the ADI and TDI. Food Addit Contam 1998; 15(suppl):17-35.
117. Hattis D, Russ A, Banati P, Kozlak M, Goble R, Ginsberg G, Smolenski S. Background and User's Guide: Comparative Child/Adult Pharmacokinetic Database based upon the Therapeutic Drug Literature. September, 2001, http://www2.clarku.edu/faculty/dhattis/CHLDPKDATABASE-USER-GUIDE.DOC.
118. Ginsberg G, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M, Smolenski S, Goble R. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci 2002; 66:185-200.
119. de Zwart LL, Haenen HEMG, Versantvoort CHM, Sips AJAM. Pharmacokinetics of ingested xenobiotics in children: a comparison with adults. RIVM Report 623860011/2002 (2002), http://www.rivm.nl/bibliotheek/rapporten/623860011.html.
120. Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharm Exp Therap 2002; 300:355-360.
121. Clewell HJ, Teeguarden J, McDonald T, Sarangapani R, Lawrence G, Covington T, Gentry R, Shipp A. Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Crit Rev Toxicol 2002; 32:329-389.
122. Insel PA. Analgesic-antipyretic and antiinflammatory agents. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman's The Phamacological Basis of Therapeutics. 9 ed. New York: McGraw-Hill, 1996:632.
123. McCarver DG, Hines RN. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharm Exp Therap 2002; 300:361-366.
124. Renwick AG. Toxicokinetics in infants and children in relation to the ADI and TDI. Food Addit Contam 1998; 15(suppl):17-35.
125. Kearns GL, Reed MD. Clinical pharmacokinetics in infants and children. A reappraisal. Clin Pharmacokinet 1989; 17(suppl 1):29-67.
126. Mushak P. Gastro-intestinal absorption of lead in children and adults: overview of biological and biophysico-chemical aspects. Chem Speciat Bioavail 1991; 3:87-104.
127. Shargel L, Yu ABC. Applied Biopharmaceutics and Pharmacokinetics. Connecticut: Appleton and Lange, 1993.
128. Du Souich P, Verges J, Erill S. Plasma protein binding and pharmacological response. Clin. Pharmacokinet 1993; 24:435-440.
129. D'Arcy PF, McElnay JC. Drug interactions involving the displacement of drugs from plasma protein and tissue binding sites. Pharmacol Ther 1982; 17:211-220.
130. Mahmood I. Interspecies scaling: role of protein binding in the prediction of clearance from animals to humans. J Clin Pharmacol 2000; 40:14294-1446.
131. Puigdemont A, Arboix M, Gaspari F, Bortolotti A, Bonati M. In-vitro plasma protein binding of propafenone and protein profile in eight mammalian species. Res Commun Chem Pathol Pharmacol 1989; 64:435-440.
132. Klotz U, Antonin KH, Bieck PR. Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig, and rat. J Pharmacol Exp Ther 1976; 199:67-73.
133. Lin JH, Chen IW, Deluna FA. Nonlinear kinetics ofaldronate. Plasma protein binding and bone uptake. Drug Metab Disp 1994; 22:400-405.
134. Kutzhals P, Havelund S, Jonassen I, Kiehr B, Riebel U, Marussen J. Albumin binding and time action of acylated insulins in various species. J Pharm Sci 1996; 85:304-308.
135. Riviere JE. Comparative Pharmacokinetics: Principles, Techniques and Applications. Ames, IA: Iowa State University Press, 1999:101.
136. Erhlinger S. Physiology of bile secretion and enterohepatic circulation. In: Johnson LR, ed. Physiology of the Gastrointestinal Tract. 2d ed. New York: Raven Press, 1987:1557.
137. Duggan DE, Kwan KC. Enterohepatic recirculation of drugs as a determinant of therapeutic ratio. Drug Metab Rev 1979; 9:21-41.
138. Pahlman I, Andersson S, Gunnarsson K, Odell ML, Wilen M. Extensive biliary excretion of the sulfasalazine analogue, susalimod, but different concentrations in the bile duct in various animal species correlating to species-specific hepatobiliary toxicity. Pharmacol Toxicol 1999; 85:123-129.
139. Traynor OJ, Dozois RR, DiMango EP. Canine interdigestive and postprandial gallbladder motility and emptying. J Physiol 1984; 246:G426-G432.
140. Oberle RL, Amidon GL. The influence of variable gastric emptying and transit rates on the plasma level curve of cimetidine: and explanation for the double peak phenomenon. J Pharmacokin Biopharm 1987; 15:529-544.
141. Vonk RJ, VanDoorn ABD, Strubbe JH. Bile secretion and bile composition in freely moving unanaesthetized rats with a permanent biliary drainage: influence of food intake on bile flow. Clin Sci Mol Med 1978; 55:253-259.
142. Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 1986; 75:1028-1040.
143. Hu TM, Hayton WL. Allometric scaling of xenobiotic clearance: uncertainty versus universality. AAPS PharmSci 3(4) article 29, 2001.
144. Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 1982; 10: 201-227.
145. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997; 276:122-126.
146. Dodds PS, Rothman DH, Weitz JS. Re-examination of the "3/4-law" of metabolism. J Theor Biol 2001; 209:9-27.
147. West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999; 284:1677-1679.
148. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 1991; 8:1351-1359.
149. Travis CC. Interspecies extrapolation in risk analysis. Ann Ist Super Sanita 1991; 27:581-594.
150. CDER Draft Guidance for Industry and reviewers: Estimating the safe starting dose in clinical trials for therapeutics in human adult volunteers, November, 2002.
151. Watanabe K, Bois BF, Zeise L. Interspecies extrapolation: a reexamination of acute toxicity data. Risk Anal 1992; 12:301-310.
152. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 1997; 13:407-484.
153. Mordenti J, Chappell W. The use of interspecies scaling in toxicokinetics. In: Yacobi A, Skelly JP, Batra VK, eds. Toxicokinetics and New Drug Development. New York: Pergamon, 1989:42-96.
154. Lave T, Levet-Trafit B, Schmitt-Hoffman A, Morgenroth B, Richter W, Chou RC. Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformation. J Pharm Sci 1995; 84:1285-1290.
155. Sarver JG, White D, Erhardt P, Bachmann K. Estimating xenobiotic half-lives in humans from rat data: influence of log P. Environ Health Perspect 1997; 105:1204-1209.
156. National Research Council (NRC). Drinking Water and Health. Vol. 6. Washington, DC: National Academy Press, 1986.
157. Dedrick RL. Animal scale-up. J Pharmacokinet Biopharm 1973; 1:435-461.
158. Tannenbaum S, Boxenbaum H, Mayersohn M. Allometric analysis of organ extraction ratios. J Pharm Sci 1997; 86:1319-1320.
159. Voisin EM, Ruthsatz M, Collins JM, Hoyle PC. Extrapolation of animal toxicity to humans: interspecies comparisons in drug development. Regul Toxicol Pharmacol 1990; 12:107-116.
160. Mahmood I. Interspecies scaling: is a priori knowledge of cytochrome P450 isoenzymes involved in drug metabolism helpful in prediction of clearance in humans from animal data? Drug Metabol Drug Interact 2001; 18:135-147.
161. Dedrick RL, Bischoff KB, Zakarko DS. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 1970; 54:95-101.
162. Diehl KH, Hul R, Morton D, Pfister R, Rabemampianina Y, Smith D, Vidal JM, van de Vorstenbosch C. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 2001; 21:15-23.
163. Wong AH, Kulandavelu S, Whiteley KJ, Qu D, Langille L, Adamson SL. Maternal cardiovascular changes during pregnancy and postpartum in mice. Am J Physiol Heart Circ Physiol 2002; 282:H918-H925.
164. Zhou R, Pickup S, Glickson JD, Scott CH, Ferrari VA. Assessment of global and regional myocardial function in the mouse using cine and tagged MRI. Magn Reson Med 2003; 49:760-764.
165. Mordenti J. Forecasting cephalosporin and monobactam antibiotic half-lives in humans from data collected in laboratory animals. Antimicrob Agents Chemother 1985; 27:887-891.
166. Boxenbaum H. Time concepts in physics, biology, and pharmacokinetics. J Pharm Sci 1986; 75:1053-1062.
167. Boxenbaum H, Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 1983; 245:R768-R774.
168. Dedrick RL, Morrison PF. Carcinogenic potency of alkylating agents in rodents and humans. Cancer Res 1992; 52:2464-2467.
169. Mahmood I, Balian JD. Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 1996; 26:887-895.
170. Feng MR, Loue X, Brown RR, Hutchaleelaha A. Allometric pharmacokinetic scaling: towards the prediction of human oral pharmacokinetics. Pharm Res 2000; 17:410-418.